The antifibrinolytic effect of lipoprotein(a) in heterozygous subjects is modulated by the relative concentration of each of the apolipoprotein(a) isoforms and their affinity for fibrin

European Journal of Clinical Investigation

Volumn 26, Issue 5, 1996, Pages 411-417

  Hervio, L ^b   Girard Globa, A ^a   Durlach, V ^c   Angles Cano E ^b  

^a EMI 0112 Faculte de Medecine Bichat   (France)

^b BICÊTRE HOSPITAL   (France)

^c REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

Apo(a); apolipoprotein(a); atherosclerosis; lipoprotein(a); Lp(a); plasminogen; thr ombosis

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A; PLASMINOGEN;

ARTICLE; ATHEROSCLEROSIS; FIBRINOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THROMBOGENESIS; THROMBOSIS;

EID: 0029898657     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1996.156288.x     Document Type: Article

References (40)

1. Scott J. Thrombogenesis linked to atherogenesis at last? Nature 1989;341:22-3.
2. Dahlen GH, Guyton JR, Arrar M, Farmer JA, Kautz JA, Gotto AM. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758-65.
3. McLean JW, Tomlinson JE, Kuang WJ et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132-7.
4. Eaton DL, Fless GM, Kohn WJ et al. Partial amino acid sequence of apolipoprotein(a) shows that is homologous to plasminogen. Proc Natl Acad Sci USA. 1987;84:3224-8.
5. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993;2:933-40.
6. Marcovina SM, Zhang ZH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between american blacks and whites. Biochem Biophys Res Comm 1993;191:1192-6.
7. Llyas Kamboch M, Ferrell RE, Kottke BA. Expressed hypervariable polymorphism of apolipoprotein(a). Am J Hum Genet 1991;49:1063-74.
8. Vali Z, Patthy L. Location of the intermediate and high affinity ω-aminocarboxylic acid-binding sites in human plasminogen. J Biol Chem 1982;257:2104-10.
9. Rouy D, Grailhe P, Nigon F, Chapman MJ, Anglés-Cano E. Lipoprotein(a) impairs generation of plasmin by fibrin bound tissue-type plasminogen activator. Arterioscler Thromb 1991; 11:629-38.
10. Harpel PC, Gordon BR, Parker TS. Plasmin catalyses binding of lipoprotein(a) to immobilized fibrinogen and fibrin. Proc Natl Acad Sci USA 1989;86:3847-51.
11. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990;10:240-5.
12. Hajjar KA, Gavish D, Breslow JL, Nachman RL. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature 1989;339:303-5.
13. Miles LA, Fless GM, Levin EG, Scanu AM, Plow EF. A potential basis for the thrombotic risks associated with lipoprotein(a). Nature 1989;339:301-3.
14. Guevara J, Jan YJ, Knapp R, Tulinsky A, Morrisett JD. Comparison of ligand-binding sites of modeled apo(a) kringle-like sequences in human lipoprotein(a). Arterioscler Thromb 1993;13:758-70.
15. Scanu AM, Miles LA, Fless GM et al. Rhesus monkey lipoprotein(a) binds to lysine sepharose and U937 monocytoid cells less efficiently than in human lipoprotein(a). J Clin Invest 1993; 91:283-91.
16. Utermann G, Menzel H, Kraft H, Duba H, Kemmler H, Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987; 80:458-65.
17. Hervio L, Chapman MJ, Thillet J, Loyau S, Anglés-Cano E: Does apolipoprotein (a) heterogeneity influence lipoprotein(a) effects on fibrinolysis? Blood 1993;82:392-7.
18. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992;90:52-9.
19. Kraft HG, Sandholzer C, Menzel HG, Utermann G. Apolipoprotein(a) alleles determine lipoprotein(a) particle density and concentration in plasma. Arterioscler Thromb 1992;12:302-6.
20. Fless GM, Rolih C, Scanu AM. Heterogeneity of human plasma lipoprotein(a). Isolation and characterization of the lipoprotein subspecies and their apoproteins. J Biol Chem 1984;259:11470-8.
21. Swaney JB, Orishimo M, Girard A: Enzymatically induced alterations in the structure of rat serum lipoproteins. J Lipid Res 1987;28:982-92.
22. Khyse-Andersen J. Electroblotting of multiple gels: a single apparatus without buffer tank for rapid transfer of protein from polyacrylamide to nitrocellulose. J Biochem Biophys Methods 1984;10:203-9.
23. Fleury V, Anglés-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991;30:7630-8.
24. Kazal LA, Amsel S, Miller OP, Tocantins LM. The preparation and some properties of fibrinogen precipitated from human plasma by glycine. Proc Soc Exp Biol Med 1963;113:989-94.
25. Grailhe P, Boyer-Neuman C, Haverkate F, Grimbergen J, Larrieu MJ, Anglés-Cano E. The mutation in fibrinogen Bicêtre II (γAsn308, Lys) does not affect the binding of t-PA and plasminogen to fibrin. Blood Coag Fibrinol 1993;4:679-87.
26. Rouy D, Koschinsky ML, Fleury V, Chapman MJ, Anglés-Cano E. Apolipoprotein(a) and plasminogen interactions with fibrin: a study with recombinant apolipoprotein(a) and isolated plasminogen fragments. Biochemistry 1992;31:6333-9.
27. Petersons GL. A simplification of the protein assay of Lowry et al. which is more generally applicable. Anal Biochem 1977;15: 45-52.
28. Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966;15:45-52.
29. Cobbaert C, Kesteloot H. Serum lipoprotein(a) levels in racially different populations. Am J Epidemiol 1992;136:441-9.
30. Utermann G. The mysteries of lipoprotem(a). Science 1989;246: 904-10.
31. Sandholzer CH, Boerwinkle E, Saha N, Tong MC, Utermann G. Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest 1992;89:1040-6.
32. Sandholzer CH, Saha N, Kark JD et al. Apo(a) isoforms predict risk for coronary heart disease. A study of six populations. Arterioscler Thromb 1992;12:1214-26.
33. Mölgaard J, Klausen IC, Lassvik C, Faergeman O, Gerdes LU. Olsson AG. Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication. Arterioscler Thomb 1992;12:895-901.
34. Kark JD, Sandholzer C, Friedlander Y, Utermann G. Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the Jerusalem population. Atherosclerosis 1993;139-151.
35. Durrington PN, Ishola M, Hunt L, Arrol S. Apolipoproteins (a), AI and B and parental history in man with early onset ischaemic heart disease. Lancet 1988;1:1070-3.
36. Oloffson BO, Dahlen G, Bilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur J Heart 1989;1:77-82.
37. Haffner SM, Moss SE, Klein BE, Klein R. Lack of association between Lp(a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin epidemiologic Study of Diabetic Retinopathy. Metabolism 1992;41:194-7.
38. Jauhiainen M, Koskinen P, Ehnholm C et al. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991;89: 59-67.
39. Ridker PM, Hennekens CH, Stamper MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993;270:2195-9.
40. Hervio L, Durlach V, Girard-Globa A, Anglés-Cano E. Multiple binding with identical linkage: a mecanism that explains the effect of lipoprotein(a) on fibrinolysis. Biochemistry 1995;34: 595-606.